FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing troubles for the franchise.